StreetInsider.com News Articles

Form SCHEDULE 13G/A Korsana Biosciences, Filed by: J. WOOD CAPITAL ADVISORS LLC

Thu, 15 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261015/27193806.html

Form DEF 14A Korsana Biosciences, For: Nov 13

Thu, 15 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261015/27193574.html

Form SCHEDULE 13G/A Korsana Biosciences, Filed by: FMR LLC

Wed, 07 Oct 2026 11:47:00 -0400

si-local-file:///var/storage/secattach/20261007/27159975.html

Form PRE 14A Korsana Biosciences, For: Oct 05

Mon, 05 Oct 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20261005/27148931.html

Wedbush Starts Korsana Biosciences (KRSA) at Outperform

Mon, 05 Oct 2026 07:04:29 -0400

(Updated - October 5, 2026 7:04 AM EDT)

Wedbush analyst Laura Chico initiates coverage on Korsana Biosciences (NASDAQ: KRSA) with a Outperform rating and a price target of $44.00.

The analyst comments "We are initiating coverage of Korsana Biosciences (KRSA) with an Outperform rating and $44 target. Simply put, Alzheimer's disease (AD) remains an area of high unmet need. Approved amyloid-targeted agents (e.g. Leqembi, Kisunla) now annualize at ~$1.4B in global end-user sales; however, commercial uptake remains constrained and agents are not without safety limitations. We see KRSA's next-gen anti-amyloid-ß KRSA-028 offering about as much de-risking as one can get in AD.

Wedbush Starts Korsana Biosciences (KRSA) at Outperform

Mon, 05 Oct 2026 07:04:29 -0400

(Updated - October 5, 2026 7:04 AM EDT)

Wedbush analyst Laura Chico initiates coverage on Korsana Biosciences (NASDAQ: KRSA) with a Outperform rating and a price target of $44.00.

Guggenheim Starts Korsana Biosciences (KRSA) at Buy

Mon, 28 Sep 2026 06:09:06 -0400

Guggenheim analyst Yatin Suneja initiates coverage on Korsana Biosciences (NASDAQ: KRSA) with a Buy rating and a price target of $70.00.

For an analyst ratings summary and ratings history on Korsana Biosciences click here. For more ratings news on Korsana Biosciences click here.

Shares of Korsana Biosciences closed at $31.00 yesterday.

Form 144 Korsana Biosciences, Filed by: DESOUZA ERROL B

Wed, 23 Sep 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260923/27097244.html

Form 144 Korsana Biosciences, Filed by: DESOUZA ERROL B

Tue, 22 Sep 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260922/27091661.html

Form SCHEDULE 13G Korsana Biosciences, Filed by: GENERAL ATLANTIC, L.P.

Fri, 18 Sep 2026 19:20:00 -0400

si-local-file:///var/storage/secattach/20260918/27081517.html

Form 144 Korsana Biosciences, Filed by: DESOUZA ERROL B

Fri, 18 Sep 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260918/27081106.html

Form SCHEDULE 13G Korsana Biosciences, Filed by: Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

Wed, 16 Sep 2026 07:56:00 -0400

si-local-file:///var/storage/secattach/20260916/27067551.html

TD Cowen Starts Korsana Biosciences (KRSA) at Buy

Mon, 14 Sep 2026 05:30:18 -0400

TD Cowen analyst Tyler Van Buren initiates coverage on Korsana Biosciences (NASDAQ: KRSA) with a Buy rating.

The analyst comments "We believe Korsana has the superior brain shuttle technology for AD as KRSA-028 is designed with improved pyroglu-Aβ targeting, enhanced brain penetration, avoidance of anemia, and subQ administration. With initial PhI/II data due in '27, we believe 028 could emerge as a BIC anti-amyloid therapy and initiate with a Buy rating. We estimate $5.3B of sales by 2040, with additional upside from THETA."

For an analyst ratings summary and ratings history on Korsana Biosciences click here. For more ratings news on

TD Cowen Starts Korsana Biosciences (KRSA) at Buy

Mon, 14 Sep 2026 05:30:18 -0400

TD Cowen analyst Tyler Van Buren initiates coverage on Korsana Biosciences (NASDAQ: KRSA) with a Buy rating.

For an analyst ratings summary and ratings history on Korsana Biosciences click here. For more ratings news on

Stifel Starts Korsana Biosciences (KRSA) at Buy

Mon, 14 Sep 2026 03:50:55 -0400

Stifel analyst Paul Mattheis initiates coverage on Korsana Biosciences (NASDAQ: KRSA) with a Buy rating and a price target of $43.00.

The analyst comments "We are initiating coverage of KRSA with a Buy rating and a $43 target price. Korsana is a neuroscience focused biotech company that is pioneering the advancement of multiple drug candidates from their proprietary BBB (blood-brain barrier) delivery platform--"THETA". The lead candidate is KRSA-028, a pyroglutamate-targeting anti-abeta antibody that is entering ph1 testing, with clinical data expected in 2027. Our bullish thesis on the stock is predicated on: (1) a view that BBB shuttles, along with additional

Stifel Starts Korsana Biosciences (KRSA) at Buy

Mon, 14 Sep 2026 03:50:55 -0400

Stifel analyst Paul Mattheis initiates coverage on Korsana Biosciences (NASDAQ: KRSA) with a Buy rating and a price target of $43.00.

UBS Starts Korsana Biosciences (KRSA) at Buy

Fri, 11 Sep 2026 03:14:49 -0400

UBS analyst Michael Yee initiates coverage on Korsana Biosciences (NASDAQ: KRSA) with a Buy rating and a price target of $55.00.

The analyst comments: “We are initiating coverage of Korsana Biosciences KRSA at BUY with a $55 price target. We view lead asset KRSA-028 as a potential best-in-class treatment for early Alzheimer's disease leveraging brain shuttle tech to increase brain exposure and amyloid clearance while reducing ARIA risk and enabling more convenient dosing. Roche's trontinemab uses a similar TfR brain shuttle tech and had strong Phase I/II data with high efficacy and strong safety and pushed to Phase III which helps

UBS Starts Korsana Biosciences (KRSA) at Buy

Fri, 11 Sep 2026 03:14:49 -0400

UBS analyst Michael Yee initiates coverage on Korsana Biosciences (NASDAQ: KRSA) with a Buy rating and a price target of $55.00.